Anika maintains 2025 revenue ranges by channel as follows: Commercial Channel, unchanged, of $47 to $49.5 million, up 12% to 18% year over year; OEM Channel, unchanged, of $62 to $65 million, down 16% to 20% year over year. Anika maintains Adjusted EBITDA as a percent of revenue of positive 3% to negative 3%.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIK:
- Anika Therapeutics reports Q3 adjusted EPS 4c vs. 7c last year
- Is ANIK a Buy, Before Earnings?
- Anika Therapeutics’ Integrity Implant System Study: A Market Game Changer?
- Anika Therapeutics: Undervalued Stock with Potential Upside Amidst Execution Challenges